Latest Commercial Execution News

HeraMED has secured pivotal US commercial agreements and achieved a key Australian regulatory milestone, positioning itself for scalable growth in digital maternity care.

Artrya Limited has converted three US foundation partners into commercial customers, generating its first fee-per-scan revenues, while progressing FDA clearance for its Salix Coronary Flow module and expanding its clinical study network.

EVE Health Group has completed manufacturing and distribution setup for Libbo™, its innovative oral dissolving film for erectile dysfunction, paving the way for near-term patient access via telehealth and pharmacy channels.

Janus Electric reports operational progress with validated technology and increased revenue, while focusing on commercial execution and cost discipline under new CEO Ben Hutt. Funding remains a critical factor for sustaining growth.

xReality Group Limited has reported its strongest quarter yet, with record cash receipts and a doubling sales pipeline, underpinned by major US defence contracts and expanded production capacity.

RemSense Technologies reported a robust Q2 FY2026 with strong Tier-1 project deliveries worth A$1.685 million and significant progress on its ISO 27001 cybersecurity certification, underpinning its digital twin platform’s growing industrial footprint.

Aurora Labs has marked a significant milestone by securing its first purchase order for micro gas turbine engines, alongside strategic MOUs with major defence groups and a $5.5 million capital raise to fuel growth.

Microba Life Sciences reports robust year-on-year growth in microbiome testing volumes and revenue, advancing towards regional break-even in Australia and the UK while progressing its therapeutic pipeline.

Compumedics has landed a $4.2 million order for its advanced MEG system from Shandong Normal University, pushing total contracted MEG sales to around $30 million and extending revenue visibility into FY27.

Algorae Pharmaceuticals has advanced its AI drug discovery capabilities with the launch of AlgoraeOS v2 and secured key commercial partnerships, including a $3 million debt facility to support expansion in Australia and New Zealand.

Environmental Clean Technologies Limited has completed the acquisition of Terrajoule, gaining exclusive rights to a cutting-edge soil remediation technology targeting PFAS contamination. The company also bolstered its leadership and funding to accelerate commercialisation.

Memphasys Limited has achieved its first material revenues following CE Mark approval for its Felix™ System, activating multi-year contracts across Europe, the Middle East, and Asia. The company is now transitioning from regulatory preparation to global commercial rollout with a focus on recurring revenues.